Drugs Containing Excipient (Inactive Ingredient) POLYVINYL ALCOHOL

Branded drugs containing POLYVINYL ALCOHOL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	INLURIYO	imlunestrant	0002-1717	POLYVINYL ALCOHOL	2030-09-25
Eli Lilly and Company	FOUNDAYO	orforglipron	0002-4178	POLYVINYL ALCOHOL	2031-04-01
Eli Lilly and Company	OLUMIANT	baricitinib	0002-4182	POLYVINYL ALCOHOL
Eli Lilly and Company	REYVOW	lasmiditan	0002-4312	POLYVINYL ALCOHOL	2040-07-06
Eli Lilly and Company	VERZENIO	abemaciclib	0002-4483	POLYVINYL ALCOHOL	2031-09-28
ER Squibb & Sons LLC	SOTYKTU	deucravacitinib	0003-0895	POLYVINYL ALCOHOL	2033-11-07
Merck Sharp & Dohme LLC	JANUVIA	sitagliptin	0006-0221	POLYVINYL ALCOHOL

Generic drugs containing POLYVINYL ALCOHOL excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	imlunestrant	0002-1717	POLYVINYL ALCOHOL
Eli Lilly and Company	orforglipron	0002-4178	POLYVINYL ALCOHOL
Eli Lilly and Company	baricitinib	0002-4182	POLYVINYL ALCOHOL
Eli Lilly and Company	lasmiditan	0002-4312	POLYVINYL ALCOHOL
Eli Lilly and Company	abemaciclib	0002-4483	POLYVINYL ALCOHOL
ER Squibb & Sons LLC	deucravacitinib	0003-0895	POLYVINYL ALCOHOL
Merck Sharp & Dohme LLC	sitagliptin	0006-0221	POLYVINYL ALCOHOL

Last updated: August 7, 2026

Polyvinyl alcohol (PVA) is a mature, price-sensitive pharmaceutical excipient with stable demand in oral solid-dose coatings, granulation, ophthalmic products, topical systems and controlled-release technologies. Its financial trajectory is tied less to proprietary drug economics than to polymer grade, regulatory qualification, supply reliability, vinyl acetate monomer costs and manufacturing capacity in Asia. Premium pharmaceutical-grade PVA can maintain margin premiums, but standard grades face commoditization and competition from hypromellose, povidone, copovidone and polyethylene glycol systems.

Polyvinyl Alcohol Pharmaceutical Excipient Market Dynamics and Financial Trajectory

What is polyvinyl alcohol and how is it used as a pharmaceutical excipient?

Polyvinyl alcohol is a synthetic, water-soluble polymer produced by hydrolysis of polyvinyl acetate. Commercial grades vary by molecular weight, degree of hydrolysis, viscosity, particle size, residual monomer profile and microbial quality.

In pharmaceutical manufacturing, PVA is used in several roles:

Application	Functional role	Commercial relevance
Film coating	Film former, binder and barrier polymer	Established demand in tablets and multiparticulates
Ophthalmic products	Viscosity enhancer and lubricant	Higher regulatory and purity requirements
Topical and transdermal products	Film former and rheology modifier	Smaller but technically differentiated segment
Granulation	Binder and mechanical-strength modifier	Competes with povidone and hydroxypropyl cellulose
Controlled release	Matrix or coating component	Niche demand tied to formulation performance
Nanoparticles and microspheres	Stabilizer or matrix polymer	Development-stage and specialty demand
Packaging and drug-delivery systems	Water-soluble or biodegradable film component	Emerging, product-specific demand

PVA is listed in the FDA Inactive Ingredient Database for certain routes and dosage forms, but an inactive-ingredient listing does not constitute blanket approval for every concentration, formulation or route of administration.[1] Sponsors must still demonstrate pharmaceutical quality, suitability for the intended use and compliance with the applicable finished-product requirements.

How large is the pharmaceutical polyvinyl alcohol market?

The pharmaceutical-only PVA market is difficult to quantify because public market reports commonly combine pharmaceutical, food, cosmetic, textile, paper, adhesive and industrial applications. Reported global PVA market estimates therefore vary materially depending on whether the analysis measures resin volume, excipient sales, formulated products or total downstream revenue.

A defensible market structure is:

1. Industrial and textile uses account for the largest share of global PVA consumption.
2. Pharmaceutical demand is a smaller specialty segment.
3. Pharmaceutical-grade material commands a price premium over general-purpose PVA.
4. Ophthalmic, coating and controlled-release applications generate higher qualification barriers than commodity industrial uses.
5. Growth in the pharmaceutical segment is driven by dosage-form innovation rather than by total PVA consumption alone.

Public company disclosures from major PVA producers generally report PVA within broader chemicals or functional-materials segments rather than as a separately disclosed pharmaceutical-excipient business. As a result, precise pharmaceutical PVA revenue, market share and EBITDA figures are generally unavailable from audited public filings.

Indicative market economics

The commercial value chain typically includes:

Value-chain stage	Main economic driver	Margin profile
Vinyl acetate monomer production	Feedstock, energy and regional capacity	Commodity-oriented
PVA polymerization and hydrolysis	Process yield, energy and equipment	Moderate
Pharmaceutical-grade finishing	Purification, milling, testing and GMP controls	Higher
Distribution and technical support	Inventory, qualification and regulatory service	Moderate to high
Finished dosage-form use	Formulation performance and regulatory approval	Highest value capture

The most attractive portion of the chain is not necessarily the polymerization step. It is the supply of tightly specified, validated grades supported by documentation, change-control discipline, analytical methods and regulatory history.

What is driving demand for pharmaceutical-grade PVA?

Oral solid-dose film coating

PVA is used in immediate-release and modified-release coating systems because it forms durable films and can provide suitable moisture and oxygen-barrier performance. It is also used in ready-to-use coating systems supplied with pigments, plasticizers and other functional excipients.

Demand depends on tablet volumes, the outsourcing of coating operations and the adoption of differentiated coating systems. PVA competes with hypromellose, hydroxypropyl cellulose, methacrylate copolymers, polyvinylpyrrolidone and cellulose derivatives.

Ophthalmic formulations

PVA has a long history in ophthalmic products as a viscosity modifier and lubricant. This segment is commercially attractive because ophthalmic formulations require tighter control over bioburden, endotoxin, impurities, viscosity and container compatibility.

The opportunity is constrained by competition from carboxymethylcellulose, hypromellose, polyethylene glycol, propylene glycol and hyaluronic-acid-based systems. PVA remains relevant where a sponsor needs a particular viscosity profile, lubrication effect or formulation history.

Controlled-release and specialty delivery

PVA can act as a matrix-forming or coating polymer in microspheres, nanoparticles and other delivery technologies. These applications can generate higher unit value but have lower volume and longer development cycles.

Specialty demand is sensitive to clinical and regulatory success. A failed product program can remove a meaningful customer account even if broader PVA demand remains stable.

Generics and contract manufacturing

Generic-drug manufacturers create recurring demand for established PVA grades used in approved formulations. Contract development and manufacturing organizations can also increase demand when they standardize coating platforms across multiple products.

The risk is purchasing concentration. A large generic manufacturer can qualify multiple suppliers, negotiate aggressively and switch between equivalent grades after comparative testing and regulatory assessment.

How do raw materials and supply chains affect PVA pricing?

PVA economics are indirectly linked to vinyl acetate monomer, which is produced from acetic acid and ethylene through industrial processes. Energy, freight, plant utilization and regional chemical capacity also affect pricing.

The main cost variables are:

• Vinyl acetate monomer prices
• Ethylene and acetic acid economics
• Electricity and steam consumption
• Plant utilization and hydrolysis efficiency
• Environmental compliance costs
• Packaging and freight
• Testing and batch-release costs
• Inventory needed to support customer qualification

Asia, particularly China and Japan, is central to global PVA production. China has substantial PVA capacity, while Japanese suppliers have strong positions in high-specification and specialty grades. European and North American pharmaceutical customers often seek dual sourcing because qualification of a replacement polymer can require formulation work, stability data and regulatory documentation.

Supply risk is highest when a customer depends on a single grade with narrow viscosity or hydrolysis specifications. A generic substitution is not always operationally simple. Differences in molecular-weight distribution, residual acetate content, particle morphology and solution behavior can affect coating weight, dissolution, tablet appearance and process performance.

Which companies supply pharmaceutical-grade polyvinyl alcohol?

The relevant supplier landscape includes large chemical manufacturers, specialty polymer companies and regional excipient distributors. Major PVA producers and suppliers associated with pharmaceutical or high-purity applications include:

Company	Relevant positioning
Kuraray	PVA and specialty polymer grades, including pharmaceutical and high-purity applications
Sekisui Chemical	PVA and functional polymer technologies
Mitsubishi Chemical-related businesses	Specialty and functional polymer capabilities
Nippon Synthetic Chemical Industry	PVA and related specialty materials
Anhui Wanwei	Large-scale PVA production, with significant Chinese market exposure
Inner Mongolia Mengwei	China-based PVA production
Regional excipient distributors	Qualification support, inventory and local regulatory service

The supplier list changes by geography and grade. A producer may manufacture the polymer while a distributor performs regional stocking, documentation support or customer qualification. Pharmaceutical buyers must distinguish between the original manufacturer, the legal supplier, the manufacturing site and the entity responsible for change notifications.

What is the regulatory status of polyvinyl alcohol in pharmaceuticals?

PVA is a recognized pharmaceutical excipient, but regulatory acceptability is use-specific. The principal regulatory considerations are:

• Route of administration
• Concentration and daily exposure
• Molecular weight and viscosity grade
• Degree of hydrolysis
• Residual vinyl acetate and other process-related impurities
• Heavy metals and elemental impurities
• Microbial quality
• Extractables and leachables
• Nitrosamine or other risk assessments where relevant
• Compatibility with the active ingredient and packaging

The FDA Inactive Ingredient Database provides precedent for certain uses and routes.[1] USP-NF and other pharmacopoeial frameworks may provide specifications or related quality expectations, but the applicable monograph and market requirements must be checked for the exact grade and jurisdiction.[2]

In Europe, excipient controls are assessed through the finished-product marketing authorization and applicable European Pharmacopoeia requirements. The European Medicines Agency’s excipient guidance emphasizes quality, safety and justification based on route and exposure.[3]

PVA suppliers targeting regulated pharmaceutical customers generally need:

• GMP or pharmaceutical-quality manufacturing controls
• A detailed specification and certificate of analysis
• Residual-solvent and residual-monomer controls
• Elemental-impurity information
• TSE/BSE statements where applicable
• Allergen and GMO statements where relevant
• Stability data
• Change-control procedures
• Auditable manufacturing and testing records

What patents protect pharmaceutical PVA formulations and manufacturing methods?

The base polymer is mature, and fundamental composition claims covering ordinary PVA are generally unlikely to provide broad, durable exclusivity in the way a new molecular entity patent does. Commercial protection is more likely to arise from:

• Specific hydrolysis and molecular-weight ranges
• Crosslinked or modified PVA compositions
• PVA-based nanoparticles and microspheres
• Drug-loaded films and ophthalmic formulations
• Controlled-release coatings
• Manufacturing methods that improve purity or particle properties
• Combination systems involving PVA and other polymers
• Device or packaging systems using PVA films

Patent risk is therefore product-specific. A PVA supplier normally cannot prevent use of the basic polymer merely through ownership of formulation patents. A drug sponsor may hold patents on a drug-PVA formulation, dosage form or delivery system, but those rights protect the finished product rather than the excipient as a commodity.

There is no general Orange Book exclusivity for PVA itself. Orange Book listings attach to approved drug products and patent claims that meet FDA listing requirements, not to excipients as standalone commercial materials.[4]

Are there Paragraph IV challenges involving PVA?

Paragraph IV litigation is directed at patents listed for an approved drug product. PVA may appear as an excipient in a formulation subject to a Paragraph IV certification, but it is not itself the target of a standalone Paragraph IV challenge.

The litigation question is whether the generic product infringes a listed formulation, method-of-use or drug-product patent. The presence of PVA in both products does not determine infringement. Claim language, concentration ranges, coating structure, release profile and other formulation limitations control.

When does polyvinyl alcohol lose exclusivity?

PVA does not have a single pharmaceutical exclusivity date. The polymer is a mature material sold by multiple manufacturers. Exclusivity can exist at narrower levels:

Exclusivity layer	Typical duration or status
Basic PVA chemistry	Mature and broadly available
Supplier-specific grade	Protected mainly by know-how, qualification and trade secrets
Drug formulation using PVA	Patent-specific, often expiring between 20 years from the earliest effective nonprovisional filing and later, if valid
Approved drug containing PVA	Drug-specific FDA exclusivity, independent of the excipient
Manufacturing process	Patent term or trade-secret protection
Customer qualification	Commercial switching barrier, not legal exclusivity

A formulation patent can remain commercially important after the underlying PVA chemistry is no longer proprietary. Conversely, a formulation patent may expire while a sponsor retains practical protection through manufacturing complexity, regulatory data, device integration or supply-chain control.

How strong is the patent estate for pharmaceutical PVA?

The patent estate for basic pharmaceutical PVA is generally weaker than the patent estate for novel polymers, biologics or drug substances. Its strength depends on the specific claim category.

Claim type	Relative protection
Generic PVA composition	Low, because of mature prior art and broad commercial availability
Narrow molecular-weight or hydrolysis range	Moderate if performance data support non-obviousness
PVA nanoparticle or microsphere system	Moderate to strong, depending on claim breadth
Drug-specific formulation	Potentially strong if clinically and commercially relevant
Purification or manufacturing process	Moderate, with design-around risk
Supplier know-how and quality system	Commercially meaningful but not equivalent to patent exclusivity

The main barriers are often technical and regulatory rather than legal. A customer may be reluctant to change suppliers because a replacement grade can affect dissolution, coating uniformity, viscosity, stability or filing commitments.

What is the financial trajectory for pharmaceutical PVA?

The financial outlook is best characterized as steady volume growth with selective margin expansion in qualified grades.

Base case

The base case assumes:

• Stable demand from generic and branded oral solid-dose products
• Moderate growth in ophthalmic formulations
• Continued use in film coating and modified-release systems
• Periodic raw-material-driven price movements
• Limited ability to raise prices for standard grades
• Higher pricing power for validated pharmaceutical grades

Under this scenario, revenue growth is likely to track a combination of pharmaceutical production growth and modest price inflation. EBITDA performance will depend heavily on plant utilization and feedstock costs.

Upside case

The upside case depends on:

• Greater use of PVA in controlled-release and advanced delivery systems
• Growth in ophthalmic and topical products
• Customer migration from commodity suppliers to higher-quality audited sources
• New ready-to-use coating platforms
• Regulatory preference for documented, traceable excipient supply
• Capacity rationalization among smaller producers

Specialty grades can generate higher margins because customers value reproducibility and regulatory support more than the lowest unit price.

Downside case

The downside case includes:

• Excess PVA capacity in China
• Weak industrial demand and aggressive export pricing
• Feedstock cost increases that cannot be passed through
• Substitution by hypromellose, povidone or synthetic coating polymers
• Customer consolidation and procurement pressure
• A quality failure, recall or regulatory warning at a major supplier
• Increased environmental costs for energy-intensive production

Financial indicators to monitor

Investors and buyers should track:

1. PVA plant operating rates in China and Japan.
2. Vinyl acetate monomer and energy prices.
3. Pharmaceutical-grade price spreads over industrial grades.
4. Qualification activity at generic-drug and CDMO customers.
5. Supplier capacity additions and shutdowns.
6. Regulatory inspection outcomes.
7. Demand for ready-to-use coating systems.
8. Revenue contribution from specialty versus commodity grades.
9. Customer concentration.
10. Inventory levels and lead times.

How does PVA compare with competing pharmaceutical polymers?

Polymer	Main strengths	Main limitations
PVA	Strong film formation, water solubility, ophthalmic history	Grade sensitivity and competition from cellulose polymers
Hypromellose	Broad pharmaceutical use, established coating systems	Different dissolution and moisture-barrier behavior
Povidone	Effective binder and solubilizer	Hygroscopicity and peroxide-related considerations
Copovidone	Strong binding and processing performance	More specialized formulation economics
Ethylcellulose	Robust sustained-release barrier	Water insolubility and solvent or dispersion requirements
Methacrylate copolymers	Tunable pH-dependent release	Higher formulation complexity and regulatory documentation
Polyethylene glycol	Plasticizer and solubilizer functions	Limited replacement for PVA’s film-forming role

PVA is most defensible where its process performance or product history is difficult to replicate. It is less defensible in applications where the excipient is selected only for basic binding or film formation.

What generic entry risks exist for drugs containing PVA?

Generic entry risk depends on the drug product, not on PVA availability. A generic manufacturer can generally purchase PVA from multiple sources, but it may need to demonstrate equivalence after changing grade or supplier.

Key risks include:

• Formulation patents covering PVA concentration or polymer combinations
• Method-of-use patents linked to release characteristics
• Drug-device patents involving PVA films or coatings
• Regulatory sensitivity to inactive-ingredient differences
• Bioequivalence failure caused by altered dissolution
• Manufacturing variability between PVA suppliers
• Patent settlements that delay launch despite excipient availability

PVA itself is unlikely to block generic entry. The relevant barriers are finished-product claims, formulation performance and regulatory evidence.

What licensing deals and commercial partnerships affect PVA?

Public disclosures generally emphasize polymer supply, distribution, formulation support and technology partnerships rather than standalone licenses for pharmaceutical PVA. Commercial arrangements are more likely to involve:

• Long-term supply agreements
• Regional distribution rights
• Ready-to-use coating technologies
• Co-development of drug-delivery systems
• Contract manufacturing and formulation services
• Technical-service agreements supporting regulatory filings

The economic value of a partnership depends on whether it locks in a qualified grade, provides dual-site manufacturing, transfers analytical methods or supports a drug product with meaningful market exclusivity.

What geographic markets offer the strongest growth?

Asia-Pacific has the broadest production base and the largest industrial demand. China is important for capacity and pricing, while Japan has a strong position in specialty and high-purity polymer manufacturing.

North America and Europe remain attractive for pharmaceutical-grade supply because customers place high value on:

• Regulatory documentation
• Audit readiness
• Supply continuity
• Change-control discipline
• Local inventory
• Technical support
• Dual sourcing

Emerging markets may grow through generic-drug manufacturing, but price sensitivity is higher and regulatory qualification standards vary.

Key Takeaways

• PVA is a mature pharmaceutical excipient with stable, diversified demand.
• The pharmaceutical segment is smaller than the industrial PVA market and is not separately reported by most public companies.
• Film coating and ophthalmic products are the most established pharmaceutical applications.
• Premium economics come from validated pharmaceutical grades, not basic PVA chemistry.
• Raw-material, energy and Asian capacity trends determine short-term pricing.
• PVA has no standalone Orange Book exclusivity and is not independently subject to Paragraph IV litigation.
• Drug-specific formulation and method-of-use patents can protect products containing PVA.
• Manufacturing know-how, qualification history and regulatory documentation create important commercial barriers.
• The base financial outlook is moderate growth with stronger margins in specialty and high-purity grades.
• The principal risks are commoditization, excess capacity, substitution and customer concentration.

FAQs

Is polyvinyl alcohol the same as polyvinylpyrrolidone?

No. PVA and polyvinylpyrrolidone are different polymers with different molecular structures, solubility profiles, hygroscopicity and pharmaceutical functions.

Can pharmaceutical companies switch between PVA suppliers?

They can, but the replacement grade must be evaluated for identity, viscosity, molecular-weight distribution, hydrolysis level, impurities, dissolution impact and process performance. Regulatory documentation may also require updating.

Is PVA suitable for injectable drug products?

PVA is more commonly associated with oral, ophthalmic, topical and delivery-system applications. Injectable use requires route-specific justification, high purity and extensive safety and quality documentation.

Does PVA create a barrier to biosimilar development?

Usually not. PVA may be present in a formulation or delivery system, but biosimilar risk is determined primarily by biologic patents, exclusivity, analytical comparability, clinical requirements and device or formulation claims.

Which PVA characteristics matter most in tablet coating?

The main characteristics are molecular weight, viscosity, degree of hydrolysis, solution clarity, particle size, residual monomer content and batch-to-batch consistency. These parameters influence coating uniformity, mechanical strength, dissolution and process yield.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary (USP-NF). United States Pharmacopeial Convention.
3. European Medicines Agency. (2017). Guideline on excipients in the label and package leaflet of medicinal products for human use. https://www.ema.europa.eu/
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
5. Kuraray Co., Ltd. (2024). Annual report and product information for polyvinyl alcohol. https://www.kuraray.com/
6. Sekisui Chemical Co., Ltd. (2024). Annual report and functional materials business information. https://www.sekisuichemical.com/